Analysts at Laidlaw initiated coverage on Gemphire Therapeutics Inc (NASDAQ: GEMP) stock, rating the company at Buy and a price target of $20.00. As a means of comparison, a number of other analysts have commented on the company recently, and …

Analysts at Laidlaw initiated coverage on Gemphire Therapeutics Inc (NASDAQ: GEMP) stock, starting the company at Buy and a price target of $20.00. As a means of comparison, a number of other analysts have commented on the stock recently, and …

Analysts at Jefferies Group initiated coverage on Gemphire Therapeutics Inc (NASDAQ: GEMP) stock, starting the company at Buy and a price target of $15.00. As a means of comparison, a number of other analysts have commented on the stock recently, …